Far Infrared Therapy Inhibits Vascular Endothelial Inflammation via the Induction of Heme Oxygenase-1

July 1, 2008

Abstract

Objective—Survival of arteriovenous fistulas (AVFs) in hemodialysis patients is associated with both far infrared (FIR) therapy and length polymorphisms of the heme oxygenase-1 (HO-1) promoter. In this study, we evaluated whether there is an interaction between FIR radiation and HO-1 in regulating vascular inflammation.

Methods and Results—Treatment of cultured human umbilical vein endothelial cells (ECs) with FIR radiation stimulated HO-1 protein, mRNA, and promoter activity. HO-1 induction was dependent on the activation of the antioxidant responsive element/NF-E2-related factor-2 complex, and was likely a consequence of heat stress. FIR radiation also inhibited tumor necrosis factor-α-mediated expression of E-selectin, vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, monocyte chemoattractant protein-1, interleukin-8, and the cytokine-mediated adhesion of monocytes to ECs. The anti-inflammatory action of FIR was mimicked by bilirubin, and was reversed by the HO inhibitor, tin protoporphyrin-IX, or by the selective knockdown of HO-1. Finally, the anti-inflammatory effect of FIR was also observed in patients undergoing hemodialysis.

Conclusions—These results demonstrate that FIR therapy exerts a potent anti-inflammatory effect via the induction of HO-1. The ability of FIR therapy to inhibit inflammation may play a critical role in preserving blood flow and patency of AVFs in hemodialysis patients.

-Arterioscler Thromb Vasc Biol. 2008 April ; 28(4): 739–745.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
July 16, 2025
FIRAPY Medical Japan proudly participated in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , held in Osaka from June 27 to 29, 2025 . This year marked a major milestone for FIRAPY in Japan: a total of 11 FIRAPY-related research presentations were featured during the congress—showcasing growing academic interest in far-infrared therapy as a supportive, non-invasive treatment in dialysis care. represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
More Posts